Endosonics Corp. said the Food and Drug Administration granted its CardioVascular Dynamics Inc. unit permission to market its "bullett infusion" catheter in the U.S.
Endosonics said its catheter delivers drugs to "preselected sites within the body" better than some other catheters.
On the Nasdaq Stock Market, the company's stock closed at $7.50, up 75 cents, or 11%.
